Cargando…
Favipiravir for the treatment of COVID-19 in elderly patients—what do we know after 2 years of COVID-19?
Since the appearance of coronavirus disease 2019 (COVID-19), numerous studies have been conducted to find effective therapeutics. Favipiravir (FVP) is one of the repurposed drugs which has been authorized in a few countries on an emergency basis to treat COVID-19. Elderly individuals especially 65 y...
Autores principales: | Papp, Henrietta, Lanszki, Zsófia, Keserű, György M., Jakab, Ferenc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091543/ https://www.ncbi.nlm.nih.gov/pubmed/35543795 http://dx.doi.org/10.1007/s11357-022-00582-8 |
Ejemplares similares
-
COVID-19: What do we know?
por: Marshall, Steve, et al.
Publicado: (2020) -
Ivermectin in COVID-19: What do we know?
por: Pandey, Sanjay, et al.
Publicado: (2020) -
COVID-19 and cancer: do we really know what we think we know?
por: Robinson, Andrew G., et al.
Publicado: (2020) -
Cardiac anesthesia and COVID-19 outbreak: What should we know?
por: Ziyaeifard, Mohsen, et al.
Publicado: (2020) -
Asthma and COVID-19: What do we know now
por: Hughes-Visentin, Alexzandra, et al.
Publicado: (2020)